drugset / Trial / NCT00100685
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) and is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Timeline
- Start
- 2005-01
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Volociximab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Volociximab | Monoclonal antibody | 15 mg/kg | Intravenous |